Housey Pharma, a commercial stage biopharmaceutical company, announced today that Mr. Henry Hadad, Senior Vice President and Deputy General Counsel of Bristol Myers Squibb, has joined its Advisory Board. Mr. Hadad has extensive experience in the pharmaceutical industry and particular expertise in intellectual property matters.
Novartis Institutes for BioMedical Research, Inc. (“Novartis”) has entered into a license agreement with Housey Pharma to utilize its core-enabling technology platform for new drug discovery. Novartis is one of the world’s top research-based pharmaceutical companies and has an impressive record of key advancements in medicine. Novartis invented the world’s first molecularly targeted cancer treatment, imatinib mesylate for the treatment of certain types of leukemia, which ushered in the next generation of oncology drugs. Novartis continues to innovate in oncology today with numerous innovative medicines at various stages of clinical testing.
Housey Pharma’s platform technology enables the creation and discovery of effective medicines for treating “undruggable” targets that are found in many human diseases, such as drug-resistant cancers, diabetes, neurodegenerative disorders including dementia, and many other disease states.
“Breakthroughs in the discovery and development of new medicines are enabled through the use of this advanced technology platform for new drug discovery,” said Dr. Gerard Housey, co-founder of the company. We look forward to seeing innovative new medicines that benefit people around the world brought forth by our scientific colleagues at Novartis as well as our many other technology licensees.”
Bristol Myers Squibb (“BMS”), one of the world’s leading oncology companies, has entered into a license agreement with Housey Pharma to license its core enabling technologies for new drug discovery directed toward difficult and “undruggable” targets in the human genome. This highly promising area of research in medicine may lead to a host of novel treatments for diseases such as drug-resistant cancers, diabetes, cardiovascular disease, CNS disorders such as dementia, and many other disease states for which current technologies are lacking.
“We are pleased to share this core technology with our scientific colleagues at Bristol Myers Squibb. We are excited by the use of these technologies throughout the industry in the in search for new medicines that will benefit people around the world,” said Dr. Gerard Housey, M.D., Ph.D., President and CEO of Housey Pharma.
Housey Healthcare’s First Clinical Trial Approved in Canada.
HPRL Awarded two Phase I Small Business Innovation Research (SBIR) Grants for its on-going research programs.
Leading Merrill Lynch Financial Advisor, Frank Migliazzo, joins Housey Pharma’s Advisory Board.